Latest Breaking News On - Jeff albers - Page 5 : comparemela.com

Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis Announced a potential best-in-class research program targeting CDK2 for the treatment of multiple cancers with tumor-associated cell cycle defects Plan to provide updates across multiple clinical and research programs at AACR 2021 Annual Meeting Ended 2020 with approximately $1.5 billion in cash News provided by Share this article Share this article CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.

United statesUnited kingdomJeff albersBecker hewesBlueprint medicines corporationEuropean commissionDrug administrationGenentech incAmerican society of hematologyExchange commissionResearch portfolioHealth care conference onPrnewswire blueprint medicines corporationEuropean medicines agencyRoche groupMedicines corporation